EACPT 2025 CONGRESS

Catch up with the foremost experts in drug interaction science at the 2025 EACPT Congress. Certara offers a mix of software and services to optimize DDI knowledge throughout drug development, including the industry’s largest scientist-curated database for assessing drug interactions and safety – the Drug Interaction Database (DIDB®)

You’ll have the opportunity to meet Isabelle Ragueneau-Majlessi, MD, MS, a Distinguished Scientist at Certara, co-founder of the DIDB and core team member of the Center of Excellence in Drug Interaction Science.

Certara’s Quantitative Systems Pharmacology (QSP) solutions combine scientific rigor with state-of-the-art QSP software to enhance decision-making at every stage of drug development. Our QSP platforms are highly scalable, enabling tailored model development to address specific therapeutic areas such as immunology, oncology, and rare diseases. By incorporating mechanistic insights and integrating diverse data sources, our solutions provide a holistic understanding of drug behavior and patient response.

With over 65 expert scientists and a track record of success across 250+ global clients, Certara delivers unparalleled expertise in QSP modeling and simulation. Whether assessing feasibility early in discovery, optimizing dose selection, predicting clinical outcomes, or de-risking R&D investments, our comprehensive approach empowers you to make smarter, faster decisions.

Meet our world-renowned QSP expert, Dr. Piet van der Graaf to find out how QSP modeling is transforming drug development from end-to-end.